S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:KOOL - Cesca Therapeutics Stock Price, Forecast & News

$2.88
+0.04 (+1.41 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$2.81
Now: $2.88
$2.89
50-Day Range
$2.84
MA: $4.35
$5.15
52-Week Range
$2.10
Now: $2.88
$7.00
Volume15,642 shs
Average Volume96,680 shs
Market Capitalization$6.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Read More…

Industry, Sector and Symbol

Industry Laboratory apparatus & furniture
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KOOL
CUSIPN/A
Phone916-858-5100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.67 million
Book Value$3.11 per share

Profitability

Net Income$-39,720,000.00

Miscellaneous

Employees53
Market Cap$6.97 million
Next Earnings DateN/A
OptionableNot Optionable

Receive KOOL News and Ratings via Email

Sign-up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter.


Cesca Therapeutics (NASDAQ:KOOL) Frequently Asked Questions

What is Cesca Therapeutics' stock symbol?

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

How were Cesca Therapeutics' earnings last quarter?

Cesca Therapeutics Inc (NASDAQ:KOOL) posted its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. View Cesca Therapeutics' Earnings History.

What price target have analysts set for KOOL?

1 brokerages have issued twelve-month price targets for Cesca Therapeutics' shares. Their forecasts range from $7.50 to $7.50. On average, they expect Cesca Therapeutics' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 160.4% from the stock's current price. View Analyst Price Targets for Cesca Therapeutics.

What is the consensus analysts' recommendation for Cesca Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cesca Therapeutics.

Has Cesca Therapeutics been receiving favorable news coverage?

News coverage about KOOL stock has trended neutral this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cesca Therapeutics earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Cesca Therapeutics.

Are investors shorting Cesca Therapeutics?

Cesca Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totalling 208,500 shares, an increase of 14.1% from the September 15th total of 182,700 shares. Based on an average daily volume of 202,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 12.1% of the company's shares are short sold. View Cesca Therapeutics' Current Options Chain.

Who are some of Cesca Therapeutics' key competitors?

What other stocks do shareholders of Cesca Therapeutics own?

Who are Cesca Therapeutics' key executives?

Cesca Therapeutics' management team includes the folowing people:
  • Dr. Xiaochun Xu M.B.A., Ph.D., Chairman, CEO & Pres (Age 48)
  • Mr. Jeff Cauble, Principal Financial & Accounting Officer (Age 46)
  • Mr. James Xu J.D., L.L.M., M.B.A., Director, Gen. Counsel, Sr. VP of Legal Affairs & Cybersecurity and Corp. Sec. (Age 48)
  • Mr. Philip H. Coelho, Chief Technology Officer (Age 75)
  • Ms. Haihong Zhu, Pres of ThermoGenesis

How do I buy shares of Cesca Therapeutics?

Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cesca Therapeutics' stock price today?

One share of KOOL stock can currently be purchased for approximately $2.88.

How big of a company is Cesca Therapeutics?

Cesca Therapeutics has a market capitalization of $6.97 million and generates $9.67 million in revenue each year. The biotechnology company earns $-39,720,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Cesca Therapeutics employs 53 workers across the globe.View Additional Information About Cesca Therapeutics.

What is Cesca Therapeutics' official website?

The official website for Cesca Therapeutics is http://www.cescatherapeutics.com/.

How can I contact Cesca Therapeutics?

Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]


MarketBeat Community Rating for Cesca Therapeutics (NASDAQ KOOL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  461
MarketBeat's community ratings are surveys of what our community members think about Cesca Therapeutics and other stocks. Vote "Outperform" if you believe KOOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel